<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">EJNMMI Res</journal-id><journal-id journal-id-type="iso-abbrev">EJNMMI Res</journal-id><journal-id journal-id-type="pmc-domain-id">1625</journal-id><journal-id journal-id-type="pmc-domain">ejnmmires</journal-id><journal-title-group><journal-title>EJNMMI Research</journal-title></journal-title-group><issn pub-type="epub">2191-219X</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12181518</article-id><article-id pub-id-type="pmcid-ver">PMC12181518.1</article-id><article-id pub-id-type="pmcaid">12181518</article-id><article-id pub-id-type="pmcaiid">12181518</article-id><article-id pub-id-type="pmid">40542294</article-id><article-id pub-id-type="doi">10.1186/s13550-025-01272-0</article-id><article-id pub-id-type="publisher-id">1272</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Quantitative renal [<sup>99m</sup>Tc]DMSA imaging predicts urinary [<sup>99m</sup>Tc]DMSA excretion in patients with chronic kidney disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0007-1150-7922</contrib-id><name name-style="western"><surname>Jensen</surname><given-names initials="D">Danny</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-9140-1701</contrib-id><name name-style="western"><surname>Andersen</surname><given-names initials="JF">Jesper Frank</given-names></name><address><email>jesper.frank@biomed.au.dk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5216-2891</contrib-id><name name-style="western"><surname>Berg</surname><given-names initials="P">Peder</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3715-7266</contrib-id><name name-style="western"><surname>Birn</surname><given-names initials="H">Henrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1326-7495</contrib-id><name name-style="western"><surname>Fl&#248;</surname><given-names initials="C">Christian</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6206-8065</contrib-id><name name-style="western"><surname>Fr&#248;ki&#230;r</surname><given-names initials="J">J&#248;rgen</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040r8fr65</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution>Department of Renal Medicine, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01aj84f44</institution-id><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Department of Biomedicine, </institution><institution>Aarhus University, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040r8fr65</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution>Department of Nuclear Medicine, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01aj84f44</institution-id><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Department of Clinical Medicine, </institution><institution>Aarhus University, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff5"><label>5</label>Department of Emergency Medicine, Goedstrup Hospital, Goedstrup, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">479053</issue-id><elocation-id>75</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>21</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-22 00:25:48.593"><day>22</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13550_2025_Article_1272.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1"><sup>99m</sup>Tc-labelled Dimercaptosuccinic acid ([<sup>99m</sup>Tc]DMSA) is a radiopharmaceutical commonly used to evaluate renal perfusion, structure, and morphology. However, the renal handling of [<sup>99m</sup>Tc]DMSA in humans remains unclear. Studies in humans with renal tubular dysfunction and animal experiments suggest that renal uptake of [<sup>99m</sup>Tc]DMSA occurs by glomerular filtration and subsequent proximal tubule reabsorption. The main aim of this study was to examine renal handling of [<sup>99m</sup>Tc]DMSA and the pathophysiological implications of [<sup>99m</sup>Tc]DMSA-based imaging in patients with chronic kidney disease (CKD) compared to healthy controls (HC).</p></sec><sec><title>Results</title><p id="Par2">Urinary excretion of [<sup>99m</sup>Tc]DMSA was 1.5-fold higher and more variable in CKD patients compared to HC. While [<sup>99m</sup>Tc]DMSA plasma clearance was only 1.1-fold higher in HC, the [<sup>99m</sup>Tc]DMSA uptake in the kidneys was 2.6-fold higher in HC compared to CKD patients and correlated inversely with the 24-hour urine excretion of [<sup>99m</sup>Tc]DMSA independent of GFR.</p></sec><sec><title>Conclusion</title><p id="Par3">Kidney [<sup>99m</sup>Tc]DMSA accumulation is consistent with tubular uptake following glomerular filtration. The relative DMSA uptake is lower in CKD patients, pointing to defective proximal tubular function in this patient group. Furthermore, the results suggest that [<sup>99m</sup>Tc]DMSA uptake could serve as a marker for tubule-interstitial function.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>DMSA scintigraphy</kwd><kwd>EDTA clearance</kwd><kwd>Chronic kidney disease</kwd><kwd>GFR</kwd><kwd>Proximal tubular function</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004915</institution-id><institution>Nyreforeningen</institution></institution-wrap></funding-source><award-id>Nyreforeningen</award-id><principal-award-recipient><name name-style="western"><surname>Jensen</surname><given-names>Danny</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006197</institution-id><institution>Fonden til L&#230;gevidenskabens Fremme</institution></institution-wrap></funding-source><award-id>13-170</award-id><principal-award-recipient><name name-style="western"><surname>Jensen</surname><given-names>Danny</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020219</institution-id><institution>Helen og Ejnar Bj&#248;rnows Fond</institution></institution-wrap></funding-source><award-id>04-121</award-id><principal-award-recipient><name name-style="western"><surname>Jensen</surname><given-names>Danny</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004824</institution-id><institution>Dansk Nefrologisk Selskab</institution></institution-wrap></funding-source><award-id>Dansk Nefrologisk Selskab</award-id><principal-award-recipient><name name-style="western"><surname>Jensen</surname><given-names>Danny</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>P. Carl Petersen Fond</institution></funding-source><award-id>11-034</award-id><principal-award-recipient><name name-style="western"><surname>Jensen</surname><given-names>Danny</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par23">Dimercaptosuccinic acid labelled with <sup>99m</sup>Tc ([<sup>99m</sup>Tc]DMSA) is widely used for non-invasive evaluation of kidney function, providing important information on renal perfusion, structure, and morphology [<xref ref-type="bibr" rid="CR1">1</xref>]. [<sup>99m</sup>Tc]DMSA is primarily used in paediatric imaging for the detection of renal scarring and parenchymal lesions, complications common to conditions like pyelonephritis and vesicoureteral reflux [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Several studies have also shown that adult patients suffering from a wide array of tubular disorders present with markedly reduced renal uptake of [<sup>99m</sup>Tc]DMSA [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. Additionally, reduced kidney [<sup>99m</sup>Tc]DMSA uptake has been observed in patients with chronic kidney disease (CKD) [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par24">Previous studies suggest that [<sup>99m</sup>Tc]DMSA accumulation in the kidney is dependent on extraction of [<sup>99m</sup>Tc]DMSA by tubular cells from the peritubular capillaries [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Conversely, an experimental study demonstrated that [<sup>99m</sup>Tc]DMSA binds to alpha-one-microglobulin (A1M) in plasma, is filtered in the glomeruli [<xref ref-type="bibr" rid="CR10">10</xref>], and reabsorbed by proximal tubule cells, followed by degradation within the lysosomal compartment [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Thus, the exact mechanism of renal [<sup>99m</sup>Tc]DMSA accumulation in humans and the pharmacokinetic properties of [<sup>99m</sup>Tc]DMSA in the kidney remain unresolved.</p><p id="Par25">CKD is defined as a persistent abnormality in renal structure or function, e.g., structural damage, a glomerular filtration rate (GFR)&#8201;&lt;&#8201;60 mL/min/1.73 m<sup>2,</sup> or urine albumin-creatinine ratio (uACR) above 30&#160;mg/g [<xref ref-type="bibr" rid="CR12">12</xref>]. Alongside glomerular dysfunction, the disease often involves impairment of proximal tubule transport [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par26">As renal [<sup>99m</sup>Tc]DMSA uptake may be dependent on the degree of proximal tubule impairment, this could potentially affect the results of a [<sup>99m</sup>Tc]DMSA scintigraphy. Previous studies indicate that a decrease in kidney [<sup>99m</sup>Tc]DMSA uptake is associated with the CKD stage [<xref ref-type="bibr" rid="CR7">7</xref>] and risk of progression [<xref ref-type="bibr" rid="CR16">16</xref>], but whether this represents a change in GFR-independent renal handling of [<sup>99m</sup>Tc]DMSA has not been established.</p><p id="Par27">Based on the conclusions of Weyer et al. [<xref ref-type="bibr" rid="CR10">10</xref>], the quantification of [<sup>99m</sup>Tc]DMSA uptake in the kidney parenchyma and the inversely correlated urinary excretion could therefore serve as a proxy for proximal tubule function, specifically in CKD patients. In CKD, disease stage and progression are conventionally monitored via filtration capacity (GFR) and glomerular barrier integrity (proteinuria), and the assessment of tubular impairment using [<sup>99m</sup>Tc]DMSA could therefore represent a novel way of evaluating CKD stage and the risk for progression.</p><p id="Par28">Thus, this study aimed to investigate renal [<sup>99m</sup>Tc]DMSA handling in CKD patients and HC and to examine whether [<sup>99m</sup>Tc]DMSA renal scintigraphy predicts urinary excretion of [<sup>99m</sup>Tc]DMSA and thereby the degree of proximal tubule dysfunction in CKD patients. To identify the physiological processing of [<sup>99m</sup>Tc]DMSA, we measured renal uptake and urinary excretion of [<sup>99m</sup>Tc]DMSA in parallel with GFR determined by [<sup>51</sup>Cr]EDTA plasma clearance.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design</title><p id="Par29">A single-centre, observational, cross-sectional study, including healthy volunteers and patients with CKD newly referred for evaluation at the Department of Renal Medicine, Aarhus University Hospital. Healthy volunteers were recruited by advertising in local newspapers.</p></sec><sec id="Sec4"><title>Inclusion of CKD patients and healthy controls</title><p id="Par30">All CKD patients were included and examined at the Departments of Renal Medicine and Nuclear Medicine and PET Centre, Aarhus University Hospital between 27 May 2013 and 27 September 2015. Inclusion criteria were: (1) age between 18 and 80 years, (2) newly referred to the renal outpatient clinic, and (3) eGFR ranging from 15 to 60&#160;ml/min/1.73m<sup>2</sup> for the last 3 months. Exclusion criteria were: (1) acute kidney failure (defined as a decline in eGFR&#8201;&gt;&#8201;50% over the last 3 months), (2) previous kidney transplantation, (3) polycystic kidney disease, glomerulonephritis or renal vasculitis, and (4) pre-existing cancer and/or a life expectancy less than 18 months.</p><p id="Par31">Inclusion criteria for healthy controls were age between 18 and 80 years old, no known renal disease or other pre-existing medical conditions, and no use of prescription medicine. Ten healthy male and ten healthy female volunteers were recruited.</p></sec><sec id="Sec5"><title>Examinations</title><p id="Par32">All participants underwent the same examination program. On the morning of the first day, a cannula for tracer injection and blood sampling was inserted into the cubital vein. Participants were instructed to empty the bladder, and a spot urine sample was collected marking the beginning of the 24-hour urine collection. At time 0, a single dose of 100 MBq [<sup>99m</sup>Tc]DMSA (Mallinckrodt DRN 4334) and 4 MBq [<sup>51</sup>Cr]EDTA (Amersham CJ.13P) were injected intravenously in a quantitative manner followed by flushing of the cannula with 20&#160;ml of normal saline. Blood samples of 9&#160;ml were drawn in potassium-EDTA coated tubes at baseline and 5, 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, and 1440&#160;min after tracer injection. Additional samples for plasma-creatinine analysis were collected in lithium/heparin-coated tubes after the 24-hour urine collection period. On the first day, blood was kept at room temperature until after the last scan (5&#160;h after tracer injection). Samples were then centrifuged, pipetted, and analysed as described below. Urine samples were collected from the 24-hour urine container 2, 5, and 24&#160;h after injection of the radiopharmaceuticals.</p><p id="Par33">Fifteen-minute gamma camera scintigrams were obtained 2- and 5-hours post-injection using a Philips Brightview dual-head gamma camera. Simultaneous anterior and posterior images were acquired in a 128&#8201;&#215;&#8201;128 matrix. The sensitivity of the two detectors was adjusted to be within a 1% difference. Attenuation of gamma rays in the patient table was ignored. Before scanning, the participants were asked to empty their bladder into a urine collection container. After the initial scan of kidneys and bladder, the urine container was scanned for 5&#160;min.</p></sec><sec id="Sec6"><title>Biochemical analyses</title><sec id="Sec7"><title>Plasma</title><p id="Par34">Plasma (P)-creatinine was analysed using a standardized, automated enzyme-linked absorption-photometric method on a Cobas<sup>&#174;</sup> 6000&#160;C machine (Roche Diagnostics International Ltd., Switzerland). eGFR was calculated using the CKD-EPI formula [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec8"><title>Urine</title><p id="Par35">All urine samples for creatinine analysis were collected in clean tubes, centrifuged, and analysed using an automated enzyme-linked absorption-photometric method on a Cobas<sup>&#174;</sup> 6000&#160;C machine (Roche Diagnostics International Ltd., Switzerland). 24-hour urine creatinine clearance (UCCl) was calculated as: UCCl&#8201;=&#8201;24-hour urine volume x 24-hour urine creatinine concentration/P-creatinine concentration.</p></sec></sec><sec id="Sec9"><title>Radio-pharmaceutical analyses</title><sec id="Sec10"><title>Plasma</title><p id="Par36">The plasma [<sup>99m</sup>Tc]DMSA and [<sup>51</sup>Cr]EDTA activity were counted in 3 mL plasma samples in a scintillation detector (Cobra II, Packard, USA) including plasma blanks and a standard dilution of tracer to a statistical accuracy of 1%. A correction was made for background, radioactive decay, and crosstalk between channels. [<sup>51</sup>Cr]EDTA activity was counted 3 days after [<sup>99m</sup>Tc]DMSA activity.</p><p id="Par37">The plasma clearance of [<sup>99m</sup>Tc]DMSA and [<sup>51</sup>Cr]EDTA were estimated as: Cl<sub>plasma</sub> = Q<sub>0</sub>/AUC, where Q<sub>0</sub> is the injected amount of tracer, and AUC is the area under the plasma curve. AUC was estimated by fitting the curve to the sum of three exponential functions using the peeling-off technique. 24-hour plasma samples were included in all plasma clearance calculations.</p></sec><sec id="Sec11"><title>Urine</title><p id="Par38">The urinary [<sup>99m</sup>Tc]DMSA-activity was determined in timed urine samples collected at 120, 300, and 1440&#160;min. A 3 mL sample of urine was drawn from a urine-collection-container after voiding and counted in a scintillation detector (Cobra II, Packard, USA) along with a standard dilution of tracer to a statistical accuracy of 1%. A correction was made for background and radioactive decay. All samples were counted for [<sup>99m</sup>Tc]DMSA after the last scan. The total urinary DMSA excretion was calculated as the activity of [<sup>99m</sup>Tc]DMSA in the urine sample multiplied by the total voided volume at the relevant time point.</p></sec><sec id="Sec12"><title>Scintigrams</title><p id="Par39">The regions of interest included the kidneys and bladder. These were defined by visual evaluation of the scintigram (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The amount of tracer in each region was determined as counts per second (CPS) within the region. Background corrections were made by drawing representative background areas for each organ, and subtracting CPS after scaling for difference in area. To compensate for differences in depth, organ CPS were measured in both anterior and posterior images, and the geometric mean (square root of the product of anterior and posterior CPS) was used as a corrected measure for organ activity. All measurements were decay-corrected back to the time of injection. Images obtained at 2&#160;h and 5&#160;h were analysed by comparing the total CPS over the kidneys in percent of the total CPS over the kidneys, bladder, and urine container. Image analysis was performed using Image-J (version 2.0.0-rc-43/1.50e) software.</p><p id="Par40">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>A representative example of a scintigram of a CKD patient and the areas used for analysis. </p><p>Figure was generated using Stata BE17.0 (StataCorp)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e590" position="float" orientation="portrait" xlink:href="13550_2025_1272_Fig1_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec251"><title>Calculations</title><p id="Par41">Accumulated kidney activity at 2&#160;h (KU2) and 5&#160;h (KU5) representing the uptake or retention in the kidneys were calculated in percent of the total <sup>99m</sup>Tc-DMSA retained in the entire urinary tract. Thus, KU2 and KU5 are believed to represent the fraction of filtered [<sup>99m</sup>Tc]DMSA accumulated in the kidneys at these time points. To further examine renal handling of DMSA, we compared the urinary excretion of [<sup>99m</sup>Tc]DMSA to the activity present in the renal and urinary tract scintigrams, both at 2&#160;h and 5&#160;h after administration of [<sup>99m</sup>Tc]DMSA. A strong linear correlation was observed between the CPS in the urine collection and the percentage of Q0 in urine at 2 and 5&#160;h, showing that scanning of the urine container is a valid measure for the excretion of the radiopharmaceutical (data not shown).</p></sec><sec id="Sec13"><title>Statistical analyses</title><p id="Par42">Data analysis and figures were made in Stata 17 (StataCorp). All data were tested for normality using visual inspection of QQ-plots comparing the experimental data to a theoretical normal distribution. Data were hereafter log transformed if needed.</p><p id="Par43">Before any linear regression analysis, the distribution of data was visually evaluated to prevent bias by heteroscedasticity. All tests were two-tailed and performed at a significance level of 5%. Students&#8217; t-test and regression analysis were used where applicable.</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Baseline characteristics</title><p id="Par44">38 CKD patients and 20 HC were included in the study. They differed significantly with respect to age, BMI, eGFR, [<sup>51</sup>Cr]EDTA-plasma clearances (GFR), and comorbidities (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par45">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinical characteristics and results of radio-pharmaceutical analyses in CKD patients and HC. <italic toggle="yes">Numbers in brackets represent SD unless followed by a %</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">CKD patients (<italic toggle="yes">n</italic>&#8201;=&#8201;38)</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Healthy Controls (<italic toggle="yes">n</italic>&#8201;=&#8201;20)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Clinical characteristics:</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">69 (9)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">24 (3)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Males (n)</td><td align="left" colspan="1" rowspan="1">21 (55%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">10 (50%)</td><td align="left" colspan="1" rowspan="1">0.34</td></tr><tr><td align="left" colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">28.6 (5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">23.7 (3.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension (n)</td><td align="left" colspan="1" rowspan="1">28 (74%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active smokers (n)</td><td align="left" colspan="1" rowspan="1">11(29%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes (n)</td><td align="left" colspan="1" rowspan="1">18 (47%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Medication:</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ca<sup>2+</sup> channel blockers (n)</td><td align="left" colspan="1" rowspan="1">20 (53%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diuretics (n)</td><td align="left" colspan="1" rowspan="1">27 (71%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ACE inhibitors/ARB (n)</td><td align="left" colspan="1" rowspan="1">25 (66%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Beta blockers (n)</td><td align="left" colspan="1" rowspan="1">17 (45%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Insulin (n)</td><td align="left" colspan="1" rowspan="1">7 (18%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Oral antidiabetics (n)</td><td align="left" colspan="1" rowspan="1">12 (32%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Statins (n)</td><td align="left" colspan="1" rowspan="1">31 (82%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Bicarbonate (n)</td><td align="left" colspan="1" rowspan="1">1 (3%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">eGFR (ml/min/1.73m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">35 (12)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">109 (15)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>Results of radio-pharmaceutical measurements:</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">[<sup>99m</sup>Tc]DMSA plasma clearance (ml/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">6.8 (1.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.8 (1.2)</td><td align="left" colspan="1" rowspan="1">0.007</td></tr><tr><td align="left" colspan="1" rowspan="1">[<sup>51</sup>Cr]EDTA plasma clearance (ml/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">35 (13)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">108 (12)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Urinary excretion of [<sup>99m</sup>Tc]DMSA (24&#160;H)</td><td align="left" colspan="1" rowspan="1">18.2% (8.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11.9% (2.5)</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>CPS relative to injected [</bold>
<sup><bold>99m</bold></sup>
<bold>Tc]DMSA:</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Kidney (2&#160;h)</td><td align="left" colspan="1" rowspan="1">3.2% (1.6)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">8.5% (1.5)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Bladder&#8201;+&#8201;urine (2&#160;h)</td><td align="left" colspan="1" rowspan="1">4.9% (3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3.8% (1.1)</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">Kidney (5&#160;h)</td><td align="left" colspan="1" rowspan="1">4.6% (2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11.9% (2.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Bladder&#8201;+&#8201;urine (5&#160;h)</td><td align="left" colspan="1" rowspan="1">10.2% (6.6)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6.5% (2.1)</td><td align="left" colspan="1" rowspan="1">0.018</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec16"><title>The plasma clearance of [<sup>99m</sup>Tc]DMSA correlated weakly with GFR and differed slightly between the groups</title><p id="Par46">The 24-hour plasma clearance of [<sup>99m</sup>Tc]DMSA revealed a weak but significant, positive correlation with [<sup>51</sup>Cr]EDTA plasma clearance in both CKD patients (r<sup>2</sup>&#8201;=&#8201;0.45, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) and HC (r<sup>2</sup>&#8201;=&#8201;0.22, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Additionally, [<sup>99m</sup>Tc]DMSA plasma clearance was marginally higher in HC (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par47">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The correlation between [<sup>99m</sup>Tc]DMSA and [<sup>51</sup>Cr]EDTA plasma clearances. A weak but statistically significant positive correlation was identified in both study groups. The linear regression fit is better in the CKD group. </p><p>Figure was generated using Stata BE17.0 (StataCorp)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e988" position="float" orientation="portrait" xlink:href="13550_2025_1272_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec17"><title>Urinary excretion of [<sup>99m</sup>Tc]DMSA differed between CKD patients and HC but was independent of GFR</title><p id="Par48">The 24-hour urinary excretion of [<sup>99m</sup>Tc]DMSA relative to the injected total dose of [<sup>99m</sup>Tc]DMSA was 1.5-fold greater in CKD patients compared to HC (18.2% vs. 11.9%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003). The 24-hour urinary [<sup>99m</sup>Tc]DMSA excretion did not correlate significantly with mGFR, measured as plasma [<sup>51</sup>Cr]EDTA clearance, in either group (HC: <italic toggle="yes">p</italic>&#8201;=&#8201;0.79, CKD: <italic toggle="yes">p</italic>&#8201;=&#8201;0.82, Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par49">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>The proportion of injected [<sup>99m</sup>Tc]DMSA excreted after 24&#160;h and [<sup>51</sup>Cr]EDTA plasma clearance. No significant correlation is present, r<sup>2</sup> is below 0.1 in all regressions. </p><p>Figure was generated using Stata BE17.0 (StataCorp)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1034" position="float" orientation="portrait" xlink:href="13550_2025_1272_Fig3_HTML.jpg"/></fig>
</p><p id="Par50">As expected, a strong, positive linear correlation was observed between the total CPS associated with the bladder and the urine container at 2 and 5&#160;h and the fraction of injected [<sup>99m</sup>Tc]DMSA excreted in the urine at 24&#160;h, both in CKD patients (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and controls (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec id="Sec262"><title>The [<sup>99&#160;m</sup>Tc]DMSA accumulation in the kidneys was independent of GFR and lower in CKD patients, correlating inversely with urinary [<sup>99&#160;m</sup>Tc]DMSA activity</title><p id="Par51">The [<sup>99m</sup>Tc]DMSA accumulation in the kidneys at 2 and 5&#160;h (KU2 and KU5) did not correlate significantly with mGFR in the CKD patients (<italic toggle="yes">p</italic>&#8201;=&#8201;0.47) or the HC (<italic toggle="yes">p</italic>&#8201;=&#8201;0.79) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). The relative kidney accumulation (kidney vs. urine&#8201;+&#8201;bladder&#8201;+&#8201;kidney accumulation) was significantly lower in CKD patients compared to HC both at 2 and 5&#160;h (2&#160;h: 0.63-fold lower, 43.7% vs. 68.9%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 and 5&#160;h: 0.55-fold lower, 35,7% vs. 64.8%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Furthermore, the kidney accumulation of [<sup>99m</sup>Tc]DMSA at 2&#160;h and 5&#160;h correlated inversely with the 24-hour urinary excretion of [<sup>99m</sup>Tc]DMSA in both CKD patients (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and HC (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par52">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>The correlation between KU2 and KU5 and [<sup>51</sup>Cr]EDTA plasma clearance. No significant correlation is identified, r<sup>2</sup> is below 0.1 in all regressions. </p><p>Figure was generated using Stata BE17.0 (StataCorp)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1100" position="float" orientation="portrait" xlink:href="13550_2025_1272_Fig4_HTML.jpg"/></fig>
</p><p id="Par53">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>The correlation between excreted [<sup>99m</sup>Tc]DMSA and KU-values in the 2 and 5-hour scans. A statistically significant, negative correlation is observed at 2 and 5&#160;h. The slope of the HC group does not differ significantly from the slope of the CKD group at any time point. The fit of the linear regression is better in the 2-hour scan and generally better in the CKD group. </p><p>Figure was generated using Stata BE17.0 (StataCorp)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1114" position="float" orientation="portrait" xlink:href="13550_2025_1272_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec266"><title>Total [<sup>99&#160;m</sup>Tc]DMSA in the urinary tract and urine (kidney, bladder, and urine collection container) was lower in CKD patients compared to HC, primarily due to decreased accumulation in the kidney</title><p id="Par54">To evaluate whether differences in urinary [<sup>99m</sup>Tc]DMSA excretion were associated with differences in the total [<sup>99m</sup>Tc]DMSA in the kidney and urogenital system, we compared the distribution of [<sup>99m</sup>Tc]DMSA in the urinary system relative to the percentage of total injected amount.</p><sec id="Sec18"><title>Two hours</title><p id="Par55">The mean total urinary tract and voided CPS (the kidney, bladder, and urine container) was significantly lower in the CKD patients compared to HC (8.1% of Q<sub>0</sub> vs. 12.3% of Q<sub>0</sub>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) representing a reduction in the urinary tract and urine activity of approximately 43% in the CKD patients. Notably, accumulation of [<sup>99m</sup>Tc]DMSA in the kidney was 62% less in CKD patients compared to HC (3.2% of Q<sub>0</sub> vs. 8.5% of Q<sub>0</sub>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), while the urinary excretion of [<sup>99m</sup>Tc]DMSA relative to the injected tracer did not differ significantly between the two groups (4.9% of Q<sub>0</sub> and 3.8% of Q<sub>0</sub>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.13). Thus, the difference in accumulated urinary tract [<sup>99m</sup>Tc]DMSA is most likely due to a combination of reduced renal plasma clearance and subsequent reduced uptake in the proximal tubules.</p></sec><sec id="Sec19"><title>Five hours</title><p id="Par56">At 5&#160;h, the mean total urinary tract and voided CPS (kidney, bladder, and urine container) did not differ between CKD patients and HC (14.8% of Q<sub>0</sub> vs. 18.4% of Q<sub>0</sub>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.25).</p><p id="Par57">Conversely, the renal accumulation of [<sup>99m</sup>Tc]DMSA was 2.6-fold higher in the HC compared to the CKD patients (11.9% of Q<sub>0</sub> vs. 4.6% of Q<sub>0</sub>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Furthermore, the CKD group presented with 1.6-fold higher urinary excretion of [<sup>99m</sup>Tc]DMSA (CPS over bladder and urine-container) compared to HC (10,2% of Q<sub>0</sub> vs. 6.5% of Q<sub>0</sub>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.018). This is consistent with a reduced kidney uptake of filtered [<sup>99m</sup>Tc]DMSA in the CKD patients.</p></sec></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par58">The present study demonstrates that renal uptake of [<sup>99m</sup>Tc]DMSA inversely correlates with the urinary excretion of [<sup>99m</sup>Tc]DMSA and is independent of GFR. This suggests a GFR-independent renal accumulation of [<sup>99m</sup>Tc]DMSA. We advocate that this is due to post-glomerular, tubular uptake of [<sup>99m</sup>Tc]DMSA, possibly mediated via proximal tubule reabsorption.</p><p id="Par59">As the renal DMSA accumulation was reduced in the CKD patients, this proposed mechanism of proximal tubular transport was impaired in the patient group. This is based on the following observations: (1) The absolute amount of [<sup>99m</sup>Tc]DMSA accumulated in the kidneys was significantly lower in the CKD patients compared to the HC, (2) the urinary excretion of [<sup>99m</sup>Tc]DMSA in the CKD patients was higher compared to the HC both 5 and 24&#160;h after injection. Thus, the fraction of injected [<sup>99m</sup>Tc]DMSA in the kidneys was significantly lower in the CKD patients compared to HC, despite comparable (at 2&#160;h) or greater (5 and 24&#160;h) urinary [<sup>99m</sup>Tc]DMSA excretion in the CKD group. This suggests that the difference in renal uptake of [<sup>99m</sup>Tc]DMSA was not due to differences in the glomerular filtration of the marker and corroborates the concept that renal [<sup>99m</sup>Tc]DMSA accumulation reflects the combined effects of filtration and subsequent tubular uptake.</p><p id="Par60">As far as we know, this GFR-independent urinary tract accumulation of [<sup>99m</sup>Tc]DMSA has not been demonstrated before. A previous study examining the relative 24-hour renal [<sup>99m</sup>Tc]DMSA uptake in 55 patients did show a correlation between GFR and [<sup>99m</sup>Tc]DMSA uptake. However, when examining patients with GFR&#8201;&lt;&#8201;20&#160;ml/min/1,73 m<sup>2</sup>, the correlation disappeared [<xref ref-type="bibr" rid="CR7">7</xref>]. As mentioned, previous studies have demonstrated a reduced renal uptake of [<sup>99m</sup>Tc]DMSA in patients suffering from a wide range of tubular disorders [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Murine experiments suggest that the reabsorption mechanism can be attributed to &#945;1-microglobulin-bound [<sup>99m</sup>Tc]DMSA being filtered and reabsorbed in the proximal tubules by megalin/cubilin-mediated endocytosis of the [<sup>99m</sup>Tc]DMSA protein complex [<xref ref-type="bibr" rid="CR10">10</xref>]. Our findings are consistent with this hypothesis, suggesting that tubular dysfunction may affect the evaluation of [<sup>99m</sup>Tc]DMSA-based renal imaging, especially in late-stage CKD patients.</p><p id="Par61">Utilising DMSA-based imaging to evaluate proximal tubular absorptive function could potentially provide new non-invasive information concerning the contribution of the proximal tubular compartment to kidney disease progression.</p><p id="Par62">Although our results, in accordance with experimental murine data [<xref ref-type="bibr" rid="CR10">10</xref>], support a tubular uptake of [<sup>99m</sup>Tc]DMSA largely independent of filtration (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>), it cannot be excluded that a critically low GFR may impair [<sup>99m</sup>Tc]DMSA accumulation.</p><p id="Par63">The plasma clearance of [<sup>99m</sup>Tc]DMSA among HC in our study was much lower than previously reported by Lange et al. [<xref ref-type="bibr" rid="CR20">20</xref>], showing a mean plasma clearance of 34&#160;ml/min in comparable healthy controls. We estimated [<sup>99m</sup>Tc]DMSA-clearance based on 24-hour plasma samples, and since filtered and reabsorbed [<sup>99m</sup>Tc]DMSA is most likely degraded in the proximal tubular cells, the 99mTc label may recirculate to plasma, thus leading to an underestimation of the renal filtration of [<sup>99m</sup>Tc]DMSA in the present study. This is supported by a study showing that 200&#160;min after the injection of <sup>14</sup>C labelled DMSA into rabbits or monkeys, no intact [<sup>99m</sup>Tc]DMSA could be identified in the plasma in any of the animals [<xref ref-type="bibr" rid="CR11">11</xref>]. However, DMSA fragments (C<sup>14</sup> activity) were identified up to 72&#160;h after tracer injection, consistent with the metabolism of labelled DMSA.</p><p id="Par64">Another explanation for the discrepancy between the clearance found in this study and the one reported by Lange et al. is difference in sampling time. Whereas our clearance was based on 24-hour plasma samples, Lange et al. had a sampling time of 4&#160;h following an equilibrium period of 1.5&#160;h.</p><p id="Par65">Furthermore, the interpretation of DMSA scans is complicated by extrarenal accumulation of the tracer and alterations in input function due to possible functional imbalances between the two kidneys of an individual.</p><p id="Par66">Several pathophysiological conditions affect the biodistribution of DMSA, mainly leading to increased accumulation in the liver [<xref ref-type="bibr" rid="CR21">21</xref>]. Acidosis has been shown to increase this extrarenal uptake of the tracer [<xref ref-type="bibr" rid="CR22">22</xref>] and could therefore confound the scan interpretation in individuals suffering from this condition, e.g. late-stage CKD patients. However, patients and controls had comparable plasma-total CO<sub>2</sub>, suggesting that acidosis is less likely to have affected the results. While differences in function between the two kidneys were not explicitly examined in the study, the decrease in renal function of the patients included in this study is typically not caused by unilateral organ affection.</p><p id="Par67">Thus, although functional imbalances between the two kidneys of an individual complicate the usage of absolute DMSA uptake as a marker of overall kidney function [<xref ref-type="bibr" rid="CR23">23</xref>], and the impact of this on the current findings is not known, we believe it is unlikely to change the overall conclusions of the study.</p><p id="Par68">Furthermore, the uptake measurement is also complicated by the semiquantitative method used for imaging, with only static images at two timepoints, and no corrections for variation in attenuation among patients.</p><p id="Par69">The CKD patients had significantly greater BMI, and thus probably more tissue in the abdominal region. This might result in an underestimation of the total uptake in the CKD patients, and thus potentially contribute to the observed difference between the patients and controls.</p><p id="Par70">All these factors hinder the usage of [<sup>99m</sup>Tc]DMSA uptake as a marker for generalised kidney function and must be taken into careful consideration when evaluating [<sup>99m</sup>Tc]DMSA uptake as a marker for proximal tubular function specifically.</p><p id="Par71">To our knowledge, this study is the first to examine the renal uptake of [<sup>99m</sup>Tc]DMSA in CKD patients compared to healthy controls. Although only 38 patients, the CKD population represented a wide spectrum of GFR, age, and co-morbidity. All experiments were performed systematically and uniformly at the same department and by the same investigator using standard methods, thus minimising any errors due to inter-individual and regional differences in handling of samples and methods, adding to the reproducibility and uniformity of our data.</p><p id="Par72">The low number of study participants limits the possibility of evaluating disease and age-specific differences in [<sup>99m</sup>Tc]DMSA handling. The healthy controls were not age-matched with the CKD group, and thus we cannot exclude an age-dependent effect on the differences in [<sup>99m</sup>Tc]DMSA handling. However, some CKD patients had a relative [<sup>99m</sup>Tc]DMSA amount comparable to individuals in the HC group, indicating it is not an age-related phenomenon. An additional limitation of the study is the lack of matching regarding comorbidities and medication between the CKD patients and controls. Several of the listed comorbidities and medications in the CKD group are known to affect kidney function and could potentially impact [<sup>99m</sup>Tc]DMSA handling as well.</p></sec><sec id="Sec21"><title>Conclusions</title><p id="Par73">The relative kidney [<sup>99m</sup>Tc]DMSA accumulation was inversely correlated with the urinary excretion of [<sup>99m</sup>Tc]DMSA and independent of GFR. This supports a GFR-independent renal recovery of [<sup>99m</sup>Tc]DMSA and is consistent with a proximal tubule-dependent uptake of [<sup>99m</sup>Tc]DMSA. Hence, caution should be shown when evaluating [<sup>99m</sup>Tc]DMSA scintigrams in patients with CKD, as differences in renal [<sup>99m</sup>Tc]DMSA accumulation may not be attributed solely to renal blood flow and filtration capacity. Furthermore, [<sup>99m</sup>Tc]DMSA scintigraphy could be utilised as a potential method for non-invasive evaluation of tubular protein reabsorption function.</p><p id="Par74">These findings hold the potential to aid the decision process for clinicians when evaluating and differentiating kidney function in CKD patients and are therefore of significant value to the field of diagnostic nuclear medicine.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>[<sup>51</sup>Cr]EDTA</term><def><p id="Par4">Chromium&#8211;51 ethylenediaminetetraacetic acid</p></def></def-item><def-item><term>[<sup>99m</sup>Tc]DMSA</term><def><p id="Par5">Technetium&#8211;99&#160;m dimercaptosuccinic acid</p></def></def-item><def-item><term>A1M</term><def><p id="Par6">Alpha&#8211;one&#8211;microglobulin</p></def></def-item><def-item><term>AUC</term><def><p id="Par7">Area under the curve</p></def></def-item><def-item><term>BMI</term><def><p id="Par8">Body mass index</p></def></def-item><def-item><term>CKD</term><def><p id="Par9">Chronic kidney disease</p></def></def-item><def-item><term>CPS</term><def><p id="Par10">Counts per second</p></def></def-item><def-item><term>eGFR</term><def><p id="Par11">Estimated glomerular filtration rate</p></def></def-item><def-item><term>GA</term><def><p id="Par12">Geometric average</p></def></def-item><def-item><term>GFR</term><def><p id="Par13">Glomerular filtration rate</p></def></def-item><def-item><term>HC</term><def><p id="Par14">Healthy controls</p></def></def-item><def-item><term>KU2</term><def><p id="Par15">Kidney uptake at 2&#160;h</p></def></def-item><def-item><term>KU5</term><def><p id="Par16">Kidney uptake at 5&#160;h</p></def></def-item><def-item><term>mGFR</term><def><p id="Par17">Measured glomerular filtration rate</p></def></def-item><def-item><term>P</term><def><p id="Par18">Creatinine&#8211;plasma creatinine</p></def></def-item><def-item><term>Q0</term><def><p id="Par19">Injected amount of tracer</p></def></def-item><def-item><term>QQ</term><def><p id="Par20">Plot&#8211;quantile&#8211;quantile plot</p></def></def-item><def-item><term>uACR</term><def><p id="Par21">Urine albumin&#8211;creatinine ratio</p></def></def-item><def-item><term>UCCl</term><def><p id="Par22">Urine creatinine clearance</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Danny Jensen and Jesper Frank Andersen shared first authorship.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Lene Elsebeth Nielsen is gratefully acknowledged for her excellent technical assistance, as is the late Michael Rehling for his sharing of basic knowledge regarding kidney physiology and nuclear medicine.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>The original conceptualization and design of the study was carried out by DJ, HB and JF. DJ was overall responsible for the inclusion of patients and controls. The data included in this paper have not been published elsewhere. The CKD patients and controls are a part of a larger cohort named the PUMA cohort. The cohort consists of a total of 82 people with CKD stage 3&#8211;4. Baseline characteristics and prospective disease progression of the PUMA cohort have been published previously [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p>DJ: conceptualisation, data analysis, writing of original draft, project administration. JFA: data analysis, review and editing, visualization, project administration. PB: data analysis, review and editing, visualization. HB: conceptualisation, data analysis, writing of original draft, review and editing, supervision, funding acquisition. CF: data analysis, resources. JF: conceptualisation, resources, supervision, funding acquisition.</p><p>All authors critically revised the manuscript and provided central comments and corrections for the final version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was conducted with financial support from the Danish Kidney Association Research Foundation, The A.P. Moeller Foundation for the Advancement of Medical Science, Helen and Ejnar Bjoernow&#8217;s Foundation, Danish Society of Nephrology, and P. Carl Petersen&#8217;s foundation.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All datasets generated and analysed during the current study are available from the corresponding author on request.</p></notes><notes><title>Declarations</title><notes id="FPar201"><title>Ethics approval and consent</title><p id="Par75">The study was approved by the Regional Ethics Committee (Committee 1, case file 1-10-72-535-12) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants prior to inclusion.</p></notes><notes id="FPar202"><title>Consent for publication</title><p id="Par76">Not applicable.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par77">HB reports speaker fees and/or serving on advisory boards for Novo Nordisk, AstraZeneca, Bayer, Boehringer Ingelheim, Galapagos, GlaxoSmithKline, Alexion, Otsuka Pharmaceuticals, MSD, and Vifor Pharma; received research grants from Novo Nordisk, GlaxoSmithKline and Vifor Pharma; and serves as chairman of the Danish Society of Nephrology and the Society&#8217;s working group on the Danish CKD guidelines outside the submitted work.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keramida</surname><given-names>G</given-names></name><name name-style="western"><surname>James</surname><given-names>JM</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>MC</given-names></name><name name-style="western"><surname>Peters</surname><given-names>AM</given-names></name></person-group><article-title>Pitfalls and limitations of radionuclide renal imaging in adults</article-title><source>Semin Nucl Med</source><year>2015</year><volume>45</volume><fpage>428</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2015.02.008</pub-id><pub-id pub-id-type="pmid">26278854</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Keramida G, James JM, Prescott MC, Peters AM. Pitfalls and limitations of radionuclide renal imaging in adults. Semin Nucl Med. 2015;45:428&#8211;39. 10.1053/j.semnuclmed.2015.02.008<pub-id pub-id-type="pmid">26278854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semnuclmed.2015.02.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Raes</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoebeke</surname><given-names>P</given-names></name><name name-style="western"><surname>Samijn</surname><given-names>W</given-names></name><name name-style="western"><surname>Delanghe</surname><given-names>J</given-names></name><name name-style="western"><surname>Vande Wiele</surname><given-names>C</given-names></name><etal/></person-group><article-title>Combined use of urinary alpha1-microglobulin and 99mTc DMSA scintigraphy in the diagnosis and follow-up of acute pyelonephritis and cystitis in children</article-title><source>Eur Urol</source><year>1998</year><volume>34</volume><fpage>486</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1159/000019788</pub-id><pub-id pub-id-type="pmid">9831790</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Everaert K, Raes A, Hoebeke P, Samijn W, Delanghe J, Vande Wiele C, et al. Combined use of urinary alpha1-microglobulin and 99mTc DMSA scintigraphy in the diagnosis and follow-up of acute pyelonephritis and cystitis in children. Eur Urol. 1998;34:486&#8211;91. 10.1159/000019788<pub-id pub-id-type="pmid">9831790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000019788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van de Wiele</surname><given-names>C</given-names></name><name name-style="western"><surname>Simons</surname><given-names>M</given-names></name><name name-style="western"><surname>Van de Walle</surname><given-names>J</given-names></name><name name-style="western"><surname>De Sutter</surname><given-names>J</given-names></name><name name-style="western"><surname>Everaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Dierckx</surname><given-names>RA</given-names></name></person-group><article-title>Age- and sex-related 99Tcm-DMSA renal uptake at 24&#160;h in children with a normal scintigram</article-title><source>Nucl Med Commun</source><year>1998</year><volume>19</volume><fpage>149</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/00006231-199802000-00009</pub-id><pub-id pub-id-type="pmid">9548199</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Van de Wiele C, Simons M, Van de Walle J, De Sutter J, Everaert K, Dierckx RA. Age- and sex-related 99Tcm-DMSA renal uptake at 24&#160;h in children with a normal scintigram. Nucl Med Commun. 1998;19:149&#8211;54. 10.1097/00006231-199802000-00009<pub-id pub-id-type="pmid">9548199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00006231-199802000-00009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Athanasoulis</surname><given-names>T</given-names></name><name name-style="western"><surname>Koutsikos</surname><given-names>J</given-names></name><name name-style="western"><surname>Zerva</surname><given-names>C</given-names></name></person-group><article-title>What is the source of the skeletal affinity of 99mTc-V-DMSA?</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2004</year><volume>31</volume><fpage>1673</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s00259-004-1650-6</pub-id><pub-id pub-id-type="pmid">15452672</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Athanasoulis T, Koutsikos J, Zerva C. What is the source of the skeletal affinity of 99mTc-V-DMSA? Eur J Nucl Med Mol Imaging. 2004;31:1673&#8211;4. 10.1007/s00259-004-1650-6. author reply 5&#8211;6.<pub-id pub-id-type="pmid">15452672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-004-1650-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D-W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C-G</given-names></name><name name-style="western"><surname>Park</surname><given-names>S-A</given-names></name></person-group><article-title>Poor renal uptake of Tc-99m DMSA in a patient with oculocerebrorenal dystrophy (Lowe syndrome)</article-title><source>Clin Nucl Med</source><year>2007</year><volume>32</volume><fpage>49</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1097/01.rlu.0000249625.75430.43</pub-id><pub-id pub-id-type="pmid">17179806</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kim D-W, Kim C-G, Park S-A. Poor renal uptake of Tc-99m DMSA in a patient with oculocerebrorenal dystrophy (Lowe syndrome). Clin Nucl Med. 2007;32:49&#8211;50. 10.1097/01.rlu.0000249625.75430.43<pub-id pub-id-type="pmid">17179806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.rlu.0000249625.75430.43</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>J</given-names></name><name name-style="western"><surname>Kume</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name><name name-style="western"><surname>Suyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Poor renal accumulation of 99mTc-DMSA in idiopathic tubular proteinuria</article-title><source>Nephron</source><year>1999</year><volume>81</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1159/000045245</pub-id><pub-id pub-id-type="pmid">9884419</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Suzuki S, Suzuki J, Kume K, Yoshida K, Suyama H, Kawasaki Y, et al. Poor renal accumulation of 99mTc-DMSA in idiopathic tubular proteinuria. Nephron. 1999;81:49&#8211;54. 10.1159/000045245<pub-id pub-id-type="pmid">9884419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000045245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Wiele</surname><given-names>C</given-names></name><name name-style="western"><surname>van den Eeckhaut</surname><given-names>A</given-names></name><name name-style="western"><surname>Verweire</surname><given-names>W</given-names></name><name name-style="western"><surname>van Haelst</surname><given-names>JP</given-names></name><name name-style="western"><surname>Versijpt</surname><given-names>J</given-names></name><name name-style="western"><surname>Dierckx</surname><given-names>RA</given-names></name></person-group><article-title>Absolute 24&#160;h quantification of 99Tcm-DMSA uptake in patients with severely reduced kidney function: a comparison with 51Cr-EDTA clearance</article-title><source>Nucl Med Commun</source><year>1999</year><volume>20</volume><fpage>829</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/00006231-199909000-00008</pub-id><pub-id pub-id-type="pmid">10533188</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">van de Wiele C, van den Eeckhaut A, Verweire W, van Haelst JP, Versijpt J, Dierckx RA. Absolute 24&#160;h quantification of 99Tcm-DMSA uptake in patients with severely reduced kidney function: a comparison with 51Cr-EDTA clearance. Nucl Med Commun. 1999;20:829&#8211;32. 10.1097/00006231-199909000-00008<pub-id pub-id-type="pmid">10533188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00006231-199909000-00008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>AM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>DH</given-names></name><name name-style="western"><surname>Evans</surname><given-names>K</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I</given-names></name></person-group><article-title>Two routes for 99mTc-DMSA uptake into the renal cortical tubular cell</article-title><source>Eur J Nucl Med</source><year>1988</year><volume>14</volume><fpage>555</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/bf00286776</pub-id><pub-id pub-id-type="pmid">2850186</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Peters AM, Jones DH, Evans K, Gordon I. Two routes for 99mTc-DMSA uptake into the renal cortical tubular cell. Eur J Nucl Med. 1988;14:555&#8211;61. 10.1007/bf00286776<pub-id pub-id-type="pmid">2850186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00286776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller-Suur</surname><given-names>R</given-names></name><name name-style="western"><surname>Gutsche</surname><given-names>HU</given-names></name></person-group><article-title>Tubular reabsorption of technetium-99m-DMSA</article-title><source>J Nucl Med</source><year>1995</year><volume>36</volume><fpage>1654</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7658227</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">M&#252;ller-Suur R, Gutsche HU. Tubular reabsorption of technetium-99m-DMSA. J Nucl Med. 1995;36:1654&#8211;8.<pub-id pub-id-type="pmid">7658227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weyer</surname><given-names>K</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>R</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>SV</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>EI</given-names></name><name name-style="western"><surname>Rehling</surname><given-names>M</given-names></name><name name-style="western"><surname>Birn</surname><given-names>H</given-names></name></person-group><article-title>Renal uptake of 99mTc-dimercaptosuccinic acid is dependent on normal proximal tubule receptor-mediated endocytosis</article-title><source>J Nucl Med</source><year>2013</year><volume>54</volume><fpage>159</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.2967/jnumed.112.110528</pub-id><pub-id pub-id-type="pmid">23232279</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Weyer K, Nielsen R, Petersen SV, Christensen EI, Rehling M, Birn H. Renal uptake of 99mTc-dimercaptosuccinic acid is dependent on normal proximal tubule receptor-mediated endocytosis. J Nucl Med. 2013;54:159&#8211;65. 10.2967/jnumed.112.110528<pub-id pub-id-type="pmid">23232279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.112.110528</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tillotson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>G</given-names></name><name name-style="western"><surname>Kincannon</surname><given-names>L</given-names></name><name name-style="western"><surname>Speckman</surname><given-names>CL</given-names></name></person-group><article-title>The biological fate of 14&#160;C-dimercaptosuccinic acid in monkeys and rabbits</article-title><source>Mil Med</source><year>1989</year><volume>154</volume><fpage>444</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/milmed/154.9.444</pub-id><pub-id pub-id-type="pmid">2552353</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tillotson JA, Boswell G, Kincannon L, Speckman CL. The biological fate of 14&#160;C-dimercaptosuccinic acid in monkeys and rabbits. Mil Med. 1989;154:444&#8211;9.<pub-id pub-id-type="pmid">2552353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>TK</given-names></name><name name-style="western"><surname>Knicely</surname><given-names>DH</given-names></name><name name-style="western"><surname>Grams</surname><given-names>ME</given-names></name></person-group><article-title>Chronic kidney disease diagnosis and management: A review</article-title><source>JAMA</source><year>2019</year><volume>322</volume><fpage>1294</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.14745</pub-id><pub-id pub-id-type="pmid">31573641</pub-id><pub-id pub-id-type="pmcid">PMC7015670</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322:1294&#8211;304. 10.1001/jama.2019.14745<pub-id pub-id-type="pmid">31573641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.14745</pub-id><pub-id pub-id-type="pmcid">PMC7015670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donadio</surname><given-names>C</given-names></name></person-group><article-title>Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary &#946;-trace protein</article-title><source>Am J Physiol Ren Physiol</source><year>2010</year><volume>299</volume><fpage>F1407</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00507.2009</pub-id><pub-id pub-id-type="pmid">20844024</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Donadio C. Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary &#946;-trace protein. Am J Physiol Ren Physiol. 2010;299:F1407&#8211;23. 10.1152/ajprenal.00507.2009<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00507.2009</pub-id><pub-id pub-id-type="pmid">20844024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraser</surname><given-names>SD</given-names></name><name name-style="western"><surname>Roderick</surname><given-names>PJ</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>C</given-names></name><name name-style="western"><surname>Fluck</surname><given-names>R</given-names></name><etal/></person-group><article-title>Assessment of proteinuria in patients with chronic kidney disease stage 3: albuminuria and non-albumin proteinuria</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e98261</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0098261</pub-id><pub-id pub-id-type="pmid">24867154</pub-id><pub-id pub-id-type="pmcid">PMC4035283</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre C, Fluck R, et al. Assessment of proteinuria in patients with chronic kidney disease stage 3: albuminuria and non-albumin proteinuria. PLoS ONE. 2014;9:e98261. 10.1371/journal.pone.0098261<pub-id pub-id-type="pmid">24867154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0098261</pub-id><pub-id pub-id-type="pmcid">PMC4035283</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fassett</surname><given-names>RG</given-names></name><name name-style="western"><surname>Venuthurupalli</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gobe</surname><given-names>GC</given-names></name><name name-style="western"><surname>Coombes</surname><given-names>JS</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hoy</surname><given-names>WE</given-names></name></person-group><article-title>Biomarkers in chronic kidney disease: a review</article-title><source>Kidney Int</source><year>2011</year><volume>80</volume><fpage>806</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.198</pub-id><pub-id pub-id-type="pmid">21697815</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806&#8211;21. 10.1038/ki.2011.198<pub-id pub-id-type="pmid">21697815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2011.198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajic</surname><given-names>M</given-names></name><name name-style="western"><surname>Ilic</surname><given-names>S</given-names></name><name name-style="western"><surname>Vlajkovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Antic</surname><given-names>S</given-names></name><name name-style="western"><surname>Velickovic</surname><given-names>L</given-names></name><name name-style="western"><surname>Stefanovic</surname><given-names>V</given-names></name></person-group><article-title>Radionuclide staging of renal function in type 1 diabetes mellitus</article-title><source>Ren Fail</source><year>2007</year><volume>29</volume><fpage>685</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1080/08860220701460061</pub-id><pub-id pub-id-type="pmid">17763163</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Rajic M, Ilic S, Vlajkovic M, Antic S, Velickovic L, Stefanovic V. Radionuclide staging of renal function in type 1 diabetes mellitus. Ren Fail. 2007;29:685&#8211;91. 10.1080/08860220701460061<pub-id pub-id-type="pmid">17763163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08860220701460061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Castro</surname><given-names>AF</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>HI</given-names></name><etal/></person-group><article-title>A new equation to estimate glomerular filtration rate</article-title><source>Ann Intern Med</source><year>2009</year><volume>150</volume><fpage>604</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604&#8211;12. 10.7326/0003-4819-150-9-200905050-00006<pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SE</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DS</given-names></name><name name-style="western"><surname>Chung</surname><given-names>JK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Poor renal uptake of technetium-99m-DMSA and technetium-99m-MDP in a patient with Fanconi syndrome and near normal glomerular filtration rate</article-title><source>J Korean Med Sci</source><year>1994</year><volume>9</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.3346/jkms.1994.9.1.29</pub-id><pub-id pub-id-type="pmid">8068216</pub-id><pub-id pub-id-type="pmcid">PMC3053909</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kim SE, Cho JT, Lee DS, Chung JK, Kim S, Lee MC, et al. Poor renal uptake of technetium-99m-DMSA and technetium-99m-MDP in a patient with Fanconi syndrome and near normal glomerular filtration rate. J Korean Med Sci. 1994;9:29&#8211;34. 10.3346/jkms.1994.9.1.29<pub-id pub-id-type="pmid">8068216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.1994.9.1.29</pub-id><pub-id pub-id-type="pmcid">PMC3053909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>BH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HG</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Decreased renal uptake of (99m)Tc-DMSA in patients with tubular proteinuria</article-title><source>Pediatr Nephrol</source><year>2009</year><volume>24</volume><fpage>2211</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s00467-009-1238-2</pub-id><pub-id pub-id-type="pmid">19579036</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lee BH, Lee SH, Choi HJ, Kang HG, Oh SW, Lee DS, et al. Decreased renal uptake of (99m)Tc-DMSA in patients with tubular proteinuria. Pediatr Nephrol. 2009;24:2211&#8211;6. 10.1007/s00467-009-1238-2<pub-id pub-id-type="pmid">19579036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00467-009-1238-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Lange</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Piers</surname><given-names>DA</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>van Luijk</surname><given-names>WH</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>S</given-names></name><name name-style="western"><surname>de Zeeuw</surname><given-names>D</given-names></name><etal/></person-group><article-title>Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake</article-title><source>J Nucl Med</source><year>1989</year><volume>30</volume><fpage>1219</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">2544699</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">de Lange MJ, Piers DA, Kosterink JG, van Luijk WH, Meijer S, de Zeeuw D, et al. Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake. J Nucl Med. 1989;30:1219&#8211;23.<pub-id pub-id-type="pmid">2544699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Fakhari A, Mamaghani F, Gharepapagh E. Dos and don&#8217;ts that are issued through radiolabeling process of DMSA (Dimercaptosuccinic acid) by 99mTco4- as 99mTc-DMSA(III), the gold standard radiopharmaceutical for renal cortical scintigraphy. J Nuclear Med Radiation Therapy. 2018;09. 10.4172/2155-9619.1000363</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yee</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HB</given-names></name><name name-style="western"><surname>Blaufox</surname><given-names>MD</given-names></name></person-group><article-title>Tc-99m DMSA renal uptake: influence of biochemical and physiologic factors</article-title><source>J Nucl Med</source><year>1981</year><volume>22</volume><fpage>1054</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6273511</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Yee CA, Lee HB, Blaufox MD. Tc-99m DMSA renal uptake: influence of biochemical and physiologic factors. J Nucl Med. 1981;22:1054&#8211;8.<pub-id pub-id-type="pmid">6273511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durand</surname><given-names>E</given-names></name><name name-style="western"><surname>Prigent</surname><given-names>A</given-names></name></person-group><article-title>Can dimercaptosuccinic acid renal scintigraphy be used to assess global renal function?</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><fpage>727</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s002590050569</pub-id><pub-id pub-id-type="pmid">10901461</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Durand E, Prigent A. Can dimercaptosuccinic acid renal scintigraphy be used to assess global renal function? Eur J Nucl Med. 2000;27:727&#8211;30. 10.1007/s002590050569<pub-id pub-id-type="pmid">10901461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002590050569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svendsen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Rousing</surname><given-names>AQ</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>RK</given-names></name><name name-style="western"><surname>Khatir</surname><given-names>D</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>D</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>NM</given-names></name><etal/></person-group><article-title>A urine pH-Ammonium acid/base score and CKD progression</article-title><source>J Am Soc Nephrol</source><year>2024</year><volume>35</volume><fpage>1533</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1681/asn.0000000000000447</pub-id><pub-id pub-id-type="pmid">39485702</pub-id><pub-id pub-id-type="pmcid">PMC11543018</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Svendsen SL, Rousing AQ, Carlsen RK, Khatir D, Jensen D, Hansen NM, et al. A urine pH-ammonium acid/base score and ckd progression. J Am Soc Nephrol. 2024;35:1533&#8211;45. 10.1681/asn.0000000000000447<pub-id pub-id-type="pmid">39485702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.0000000000000447</pub-id><pub-id pub-id-type="pmcid">PMC11543018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlsen</surname><given-names>RK</given-names></name><name name-style="western"><surname>Khatir</surname><given-names>DS</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>D</given-names></name><name name-style="western"><surname>Birn</surname><given-names>H</given-names></name><name name-style="western"><surname>Buus</surname><given-names>NH</given-names></name></person-group><article-title>Prediction of CKD progression and cardiovascular events using albuminuria and pulse wave velocity</article-title><source>Kidney Blood Press Res</source><year>2023</year><volume>48</volume><fpage>468</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1159/000530887</pub-id><pub-id pub-id-type="pmid">37279705</pub-id><pub-id pub-id-type="pmcid">PMC10389797</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Carlsen RK, Khatir DS, Jensen D, Birn H, Buus NH. Prediction of CKD progression and cardiovascular events using albuminuria and pulse wave velocity. Kidney Blood Press Res. 2023;48:468&#8211;75. 10.1159/000530887<pub-id pub-id-type="pmid">37279705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000530887</pub-id><pub-id pub-id-type="pmcid">PMC10389797</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>